This study is testing two drugs, Avutometinib (VS-6766) and defactinib, to see how well they work and if they are safe for women with certain gynecological cancers. These include endometrioid cancer, mucinous ovarian cancer, high-grade serous ovarian cancer, or other solid gynecological cancers. You may be able to join if your cancer has specific changes (mutations) in genes like RAS or BRAF, or a loss of NF-1 function. The study will look at how many patients respond to the treatment over two years. The drugs are taken by mouth for three weeks, followed by a one-week break, in each four-week cycle.

Study design

This is a Phase 2 study, meaning it's an early-stage study to see if the treatment is effective and safe. It plans to include 55 participants and is an open-label study, so both you and your doctors will know what treatment you are receiving.

What's involved

You will take the study drugs orally and attend regular study visits. These visits will include physical exams, checking vital signs, measuring your tumor size, and providing urine and blood samples. Additional visits may be needed to check for side effects.

Compensation

Not stated in the trial record.

Follow-up

The main goal of the study is measured at 2 years, which suggests follow-up will occur for at least this long.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.